Compare ACFN & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACFN | QTTB |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 40.9M |
| IPO Year | N/A | N/A |
| Metric | ACFN | QTTB |
|---|---|---|
| Price | $15.15 | $3.40 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 65.9K | ★ 392.4K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 473.47 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $12,630,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.72 | ★ N/A |
| Revenue Growth | ★ 30.11 | N/A |
| 52 Week Low | $12.42 | $1.35 |
| 52 Week High | $33.00 | $6.37 |
| Indicator | ACFN | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 62.07 |
| Support Level | $14.85 | $3.08 |
| Resistance Level | $16.09 | $3.29 |
| Average True Range (ATR) | 1.45 | 0.24 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 48.99 | 95.83 |
Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. It operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.